Usefulness of taurine in chronic congestive heart failure and its prospective application.
We compared the effect of oral administration of taurine (3 g/day) and coenzyme Q10 (CoQ10) (30 mg/day) in 17 patients with congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy, whose ejection fraction assessed by echocardiography was less than 50%. The changes in echocardiographic parameters produced by 6 weeks of treatment were evaluated in a double-blind fashion. In the taurine-treated group significant treatment effect was observed on systolic left ventricular function after 6 weeks. Such an effect was not observed in the CoQ10-treated group.
Azuma
J
J
Third Department of Internal Medicine, Osaka University Medical School, Japan.
Sawamura
A
A
Awata
N
N
D000284:Administration, Oral; D002311:Cardiomyopathy, Dilated / Q000150:complications; D002908:Chronic Disease; D003067:Coenzymes; D003327:Coronary Disease / Q000150:complications; D004311:Double-Blind Method; D004341:Drug Evaluation; D004452:Echocardiography; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D008297:Male; D013318:Stroke Volume; D013654:Taurine / Q000008:administration & dosage / Q000627:therapeutic use*; D014451:Ubiquinone / Q000031:analogs & derivatives / Q000627:therapeutic use; D016277:Ventricular Function, Left / Q000187:drug effects
D003067:Coenzymes; D014451:Ubiquinone; D013654:Taurine; C024989:coenzyme Q10